Prevalence and risk factors of hyperuricemia and gout in patients with type 2 diabetes mellitus: a systematic review and meta-analysis - Summary - MDSpire
Advertisement
Prevalence and risk factors of hyperuricemia and gout in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
To estimate the global prevalence of hyperuricemia (HUA) and gout in patients with type 2 diabetes mellitus (T2DM) and to identify associated risk factors.
Approach:
Study Selection: A systematic search was conducted in PubMed, Embase, Web of Science, and the Cochrane Library to identify observational studies on HUA/gout in T2DM patients. Two researchers independently performed literature screening, data extraction, and quality assessment.
Statistical Analysis: Statistical analyses were performed using Stata 12.0 software. A random-effects model was used to pool prevalence estimates, with subgroup and sensitivity analyses to explore heterogeneity.
Key Findings:
The pooled prevalence of HUA in T2DM patients was 22.0% (95% CI: 20.1-24.0%).
The pooled prevalence of gout in T2DM patients was 6.0% (95% CI: 4.4-7.5%).
Geographic region was identified as a significant source of heterogeneity, with the highest HUA prevalence in Africa and North America, and the lowest in South America.
Risk factors for HUA included impaired renal function, obesity, dyslipidemia, hypertension, metabolic syndrome, and alcohol consumption.
Male sex was a significant risk factor for gout.
Elevated HbA1c was inversely associated with HUA.
Interpretation:
The prevalence of HUA and gout is significantly higher in patients with T2DM compared to the general population, with specific risk factors identified.
Limitations:
The study only included observational studies, which may limit the strength of causal inferences.
Potential publication bias was assessed but not quantified.
Conclusion:
Routine serum uric acid monitoring and early screening for high-risk individuals should be incorporated into the clinical management of T2DM.
In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.
